Vaxcyte Inc (PCVX): Total Asset Value of Company

Graphic logo of Vaxcyte Corp (PCVX)

Vaxcyte, Inc. (PCVX) plans to capture the market by introducing high-margin, next-generation pneumococcal vaccines. Total asset dynamics confirm financial stability, where 3222.10 characterizes this valuation parameter. Innovative development methods minimize technological risks, while strict control over raw material supply chains ensures the continuity of production cycles for this biotech giant.

Vaxcyte, Inc. (PCVX) Company Total Assets: for the period 07/04/2022 - 10/29/2026

Comprehensive metric breakdowns and analytics for Vaxcyte Corp (PCVX)

- price and consensus price forecast:
Share Price vaxcyte.com|PCVX - Price Target Chart
- market capitalization data:
Market Valuation SutroVax|PCVX - Enterprise Value
- book capitalization data:
Accounting Value of a Share Vaxcyte|PCVX - Book Capitalization|Market Capitalization to Book Value Ratio vaxcyte.com|PCVX - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Vaxcyte, Inc.|PCVX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio SutroVax|PCVX - Company Aggregate Debts|Debts to Book Capitalization SutroVax|PCVX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Vaxcyte
Fundamental valuation:PCVX, vaxcyte.com
Finished products of Vaxcyte, Inc.

For a biotech sector investor, Vaxcyte, Inc. (PCVX) represents a high-tech asset whose value is based on the potential of successfully navigating clinical vaccine development stages. The organization's current asset value of 3222.10, reverse-calculated via ROA, reflects the aggregate of resources and liabilities required to cover capital-intensive R&D expenses, confirming the company's long-term financial stability.

Competitors of Vaxcyte, Inc. (PCVX)

SMMT (summittxinc.com) - Total Business Assets|Aggregate Company Assets Moderna MRNA|Total Asset Value of Company Tarsus Pharmaceuticals Inc|CorMedix Corp (CRMD) - Company Total Assets|Aggregate Asset Value Seres Therapeutics, Inc (MCRB)|Company Total Assets SPRO (Spero Therapeutics)|SCYNEXIS Inc - Company Total Assets|Aggregate Company Assets AN2 Bio (ANTX)|PYPD: Aggregate Asset Value|LSB (YS Biopharma) - Aggregate Company Assets|Iterum Therapeutics (ITRM) - Cumulative Company Assets|PHGE (BiomX Inc) - Company Total Assets|Company Total Assets BioPharma Bio (SNGX)|60 Degrees Pharmaceuticals (SXTP) - Cumulative Company Assets|Aggregate Asset Value oragenics.com (OGEN)|Company Total Assets ONCO|OpGen Corporation - Company Total Asset Base